scholarly journals Immune-Related Response Criteria Partial Response

2020 ◽  
Author(s):  
Keyword(s):  
Partial Response ◽  
Response Criteria ◽  
Related Response

scholarly journals Adaptation of the Immune Related Response Criteria: Irrecist

2014 ◽  
Vol 25 ◽  
pp. iv369 ◽  
Author(s):  
O. Bohnsack ◽  
A. Hoos ◽  
K. Ludajic
Keyword(s):  
Response Criteria ◽  
Related Response

CCR 20th Anniversary Commentary: Immune-Related Response Criteria—Capturing Clinical Activity in Immuno-Oncology

2015 ◽  
Vol 21 (22) ◽  
pp. 4989-4991 ◽  
Author(s):  
Axel Hoos ◽  
Jedd D. Wolchok ◽  
Rachel W. Humphrey ◽  
F. Stephen Hodi
Keyword(s):  
Response Criteria ◽  
Clinical Activity ◽  
20Th Anniversary ◽  
Related Response

Randomized phase II trial of MIBG versus MIBG/vincristine/irinotecan versus MIBG/vorinostat for relapsed/refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy Consortium.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 10500-10500
Author(s):  
Steven G. DuBois ◽  
Meaghan Granger ◽  
Susan G. Groshen ◽  
Denice Tsao-Wei ◽  
Anasheh Shamirian ◽  
...  
Keyword(s):  
Partial Response ◽  
Phase Ii ◽  
Response Rate ◽  
Phase Ii Trial ◽  
Response Rates ◽  
Response Criteria ◽  
Current Response ◽  
Minor Response ◽  
Randomized Phase Ii ◽  
Grade 3

10500 Background: 131I-metaiodobenzylguanidine (MIBG) remains one of the most active agents for neuroblastoma. It is not clear if putative radiation sensitizers improve upon this activity. The primary aim of this trial was to identify the MIBG treatment regimen with highest response rate among: MIBG monotherapy (Arm A); MIBG/Vincristine/Irinotecan (Arm B); MIBG/Vorinostat (Arm C). The secondary aim was to compare toxicity across arms. Methods: We conducted a multicenter, randomized phase II trial. Patients 1-30 years with relapsed/refractory high-risk neuroblastoma were eligible with at least one MIBG-avid site and adequate autologous stem cells (ASCs). All patients received MIBG 18 mCi/kg on Day 1 and ASC on day 15. Patients on Arm A received only MIBG; patients on Arm B also received vincristine (2 mg/m2) IV on Day 0 and irinotecan (50 mg/m2) IV daily on Days 0-4; patients on Arm C also received vorinostat (180 mg/m2) orally once daily on days -1 to 12. The primary endpoint was response after one course according to NANT response criteria. The trial was designed as a pick-the-winner study with a maximum of 105 eligible and evaluable patients to ensure an 80% chance that the arm with highest response rate is selected, if that response rate is at least 15% higher than the other arms. Results: 114 patients enrolled. Three patients were ineligible and 6 eligible patients never received MIBG, leaving 105 eligible and evaluable patients (36 Arm A; 35 Arm B; and 34 Arm C; 55 boys; median age 6.5 years). 9 patients had received prior MIBG monotherapy, 65 prior irinotecan, and 7 prior vorinostat. After one course, the response rates (Partial Response or better) on Arms A, B, and C were 17% (95% CI 7-33%), 14% (5-31%), and 32% (18-51%). An additional 4, 4, and 7 patients met NANT Minor Response criteria [partial response in one disease category (e.g., bone marrow) and stable disease in other categories] on Arms A, B, and C, respectively. On Arms A, B, and C, rates of any grade 3+ non-hematologic toxicity were 19%, 49% and 32%; rates of grade 3+ diarrhea were 0%, 11%, 0%; and rates of grade 3+ febrile neutropenia were 6%, 11%, and 0%. Conclusions: The combination of vorinostat/MIBG had the highest response rate, with manageable toxicity. Vincristine and irinotecan do not improve the response rate to MIBG and are associated with increased toxicity. These data provide response rates for MIBG monotherapy in a contemporary patient population assessed with current response criteria. Clinical trial information: NCT02035137.

scholarly journals Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements

2013 ◽  
Vol 19 (14) ◽  
pp. 3936-3943 ◽  
Author(s):  
Mizuki Nishino ◽  
Anita Giobbie-Hurder ◽  
Maria Gargano ◽  
Margaret Suda ◽  
Nikhil H. Ramaiya ◽  
...  
Keyword(s):  
Tumor Response ◽  
Response Criteria ◽  
Common Language ◽  
Related Response

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

2009 ◽  
Vol 15 (23) ◽  
pp. 7412-7420 ◽  
Author(s):  
J. D. Wolchok ◽  
A. Hoos ◽  
S. O'Day ◽  
J. S. Weber ◽  
O. Hamid ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Immune Therapy ◽  
Response Criteria ◽  
Related Response

Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 3006-3006 ◽  
Author(s):  
F. Stephen Hodi ◽  
Antoni Ribas ◽  
Adil Daud ◽  
Omid Hamid ◽  
Caroline Robert ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Advanced Melanoma ◽  
Response Criteria ◽  
Related Response
Sign in / Sign up

Export Citation Format

Share Document